Johnson & Johnson Liquidation Value

JNJ's liquidation posture is deeply negative, consistent with a large-cap pharmaceutical/medtech enterprise whose asset base is dominated by zero-recovery intangibles. MFFAIS pre-computed values confirm: cash liquidation value of approximately -$73.6B, liquid liquidation value of approximately -$55.8B, and operating liquidation value of approximately -$41.3B as of March 29, 2026.

The recovery math is straightforward. Total assets of $200.9B include goodwill of $48.6B and other intangibles (net) of $49.1B — together $97.7B, or 49% of total assets — which receive a 0% recovery haircut under the liquidation lens. PP&E gross of $54.7B carries $31.4B of accumulated depreciation, yielding net PP&E of $23.3B; applying a 50-70% recovery haircut produces $11.6B-$16.3B of realizable value. Cash and equivalents of $21.7B recover at par. AR of $17.7B recovers at 90-95%, or roughly $15.9B-$16.8B. Inventory of $14.6B recovers at approximately 60%, or $8.7B. Deferred tax assets ($6.7B), prepaid and other current ($4.8B), and other noncurrent assets ($14.1B) are largely non-recoverable or deeply uncertain in wind-down.

On the liability side, face-value obligations are substantial. Total liabilities are $119.7B, comprising $57.7B current (including $17.5B short-term debt, $10.5B AP, $7.4B accrued liabilities, $2.9B employee liabilities, and $1.1B accrued income taxes) and $62.0B noncurrent (including $37.5B long-term debt, $10.2B other noncurrent liabilities, $7.0B deferred tax liabilities). Debt totals approximately $55.0B per MD&A disclosure ($17.5B short-term plus $37.5B long-term).

Material developments this quarter: (1) Debt stack increased — net debt position is $32.9B versus $13.5B in Q1 2025, driven by $7.2B net short-term debt issuance in Q1 2026 to fund $4.0B in buybacks and $3.1B in dividends. Short-term debt alone stands at $17.5B, creating rollover concentration risk in a liquidation scenario. (2) Talc reserve sits at $3.4B (approximately one-third current), a face-value liability surviving wind-down with 75,000 active plaintiffs and securities class action proceeding now at Third Circuit. (3) The $49.1B intangibles balance (net of amortization) reflects the Intra-Cellular ($14.5B consideration, completed April 2025) and Halda ($3.05B, December 2025) acquisitions; the acquired IPR&D ($8.3B and $2.8B respectively) and amortizable intangible ($5.2B for CAPLYTA) carry zero liquidation value. (4) AOCI is a negative $14.8B, including a $0.6B cash flow hedge loss, which offsets book equity but does not affect liability face-value stack. (5) Pending Orthopaedics separation introduces structural complexity; costs already running through P&L and balance sheet. Filing discusses opioid settlements of approximately $1.1B remaining and $1.8B corporate bonds due in current period — both face-value liabilities in wind-down. The ERISA prescription-drug benefits class action was dismissed but remains on appeal.